Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2017-05-17 Director's Dealing
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-05-17 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2017, reporting the results of operations and financial condition for the quarter ended March 31, 2017. It mentions a press release and a conference call regarding quarterly results. The document includes forward-looking statements and references to the upcoming quarterly report on Form 10-Q. The content is typical of an earnings release announcement rather than a full quarterly report, as it highlights key results and provides a press release as an exhibit. The document length is about 7000 characters, which is consistent with an earnings release rather than a full interim report. Therefore, the filing type is Earnings Release (ER).
2017-05-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The content describes an announcement of a press release regarding regulatory consultations completed by the company. The document is short (2939 characters) and primarily serves to announce the press release, which is attached as an exhibit. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for filings that do not fit other specific categories.
2017-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the Annual Meeting of Stockholders, voting instructions, and proposals such as election of directors and ratification of auditors. The document is titled 'Definitive Additional Materials' related to the proxy statement, which is typical for proxy solicitation materials. It is not the Annual Report (10-K) itself, nor an announcement of voting results (DVA). It is clearly a Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders to solicit votes for the meeting. The document length (5354 characters) and content confirm it is not a brief announcement or a full financial report but proxy materials. Therefore, the correct classification is PSI with high confidence.
2017-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.